Effects of carvedilol on the activities of IFN-γand IL-12 and oxygen free radical in murine model with coxsackievirus B3-induced viral myocarditis

Abstract

Abstract: AIM: The study was designed to examine the effects of carvedilol and metoprolol in a murine model of viral myocarditis induced by coxsackievirus B3 virus infection (CVB₃). METHODS: BALB/C mice were intraperitoneally inoculated with CVB₃, at the starting 24 h after infection carvedilol was administered orally in a dose of 10 mg°kg^-1°d^-1, and metoprolol was administered orally in a dose of 30 mg°kg^-1°d^-1 for 7 or 14 consective days.Virus infection group and normal group were used with same dose PBS.Mice were killed at day 7 and 14.Myocardial histopathology changes, the HW/BW ratio, the myocardial IFN-γand IL-12 production, the content of maleic dialdehyde (MDA) and superoxide dismutase (SOD) were detected. RESULTS: Carvedilol, but not metoprolol, markedly attenuated myocardial lesions and decreased HW/BW ratio.On day 7, carvedilol group, but not metoprolol group, increased the myocardial IFN-γand IL-12 production and decreased the content of MDA more significantly than virus infection group.On day 14, carvedilol group, but not metoprolol, markedly increased the content of SOD and manifested decreased the content of MDA than virus infection group. CONCLUSION: Carvedilol protects against CVB₃-induced viral myocarditis in mice.Carvedilol exerts some of its beneficial effects by boosting the production of IFN-γ and IL-12 and inhibiting peroxidants.

Key words: carvedilol, metoprolol, interferon type, IL-12, antioxidants, myocarditis

CLC Number:

R965.2

LI Yue-chun, CHEN Peng, GE Li-sha, REN Jiang-hua. Effects of carvedilol on the activities of IFN-γand IL-12 and oxygen free radical in murine model with coxsackievirus B3-induced viral myocarditis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1101-1105.

References

[1] Pauschinger M, Doerner A, Kuehl U, et al.Eneroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis [J].Circulation, 1999, 99(7):889-895.
[2] Panina-Bordignon P, Mazzeo D, Lucia PD, et al.Beta2- agonists prevent Th1 development by selective inhibition of interleukin-12[J].J Clin Invest, 1997, 100(6):1513-1519.
[3] Andrade-Mena CE.Inhibition of gamma interferon synthesis by catecholamines[J].J Neuroimmunol, 1997, 76(1):10-14.
[4] Dulin B, Abraham WT.Pharmacology of carvedilol[J]. Am J Cardiol, 2004, 93(Suppl):3B-6B.
[5] Poole-Wilson PA, Swedberg K, Cleland JGF, et al.Comparison of carvediol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial(COMET):randomized controlled trial[J].Lancet, 2003, 362(9390):7-13.
[6] Yaoita H, Sakabe A, maehara K, et al.Different effect of carvedilol, metoprotol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats[J].Circulation, 2002, 105(8): 975-980.
[7] Henke A, Wagner E,Whitton JL, et al.Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization[J].J Viro, l998, 72(10):8327-8331.
[8] Henke A, Zell R, Stelzner A.DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice[J]. Antiviral Res, 2001, 49(1):49-54.
[9] Feldman AM, McNamara D.Myocarditis[J].N Engl J Med, 2000, 343(19):1388-1398.
[10] Tschö pe C, Westermann D, Steendijk P, et al.Hemody-Chin J Clin Pharmacol Ther 2009 Oct;14(10) namic characterization of left ventricular function in experimental coxsackieviral myocarditis:effect of carvedilol and metoprolol[J].EUR J Pharmacol, 2004, 491(2/3):173-179.
[11] Pauschinger M, Rutschow S, Chandrasekharan K, et al.Carvedilol improves left ventricular function in murine coxsackievirus- induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response[J].Eur J Heart Fail, 2005, 7(4):444-452.
[12] Sponer G, Bartsch W, Strein K, et al.Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties[J].J Cardiovasc Pharmacol, 1987, 9(3):317-327.
[13] Shioi T, Matsumori A, Nishio R, et al.Protective role of interleukin-12 in viral myocarditis[J].JMol Cell Cardiol, 1997, 29(9):2327-2334.
[14] Henke A, Zell R, Martin U, et al.Direct interferon-γ- mediated protection caused by a recombinant coxsackievirus B3[J].Virology, 2003, 315(2):335-344.
[15] Yuan Z, Shioji K, Nimata M, et al.Cardioprotective effects of carvedilol on acute autoimmune myocarditis[J]. Mol Cell Biochem, 2004, 259(1/2):223-228.
[16] Nakamura K, Kusano K, Nakamura Y, et al.Carvedilol decreases elevated oxidative stress in human failing myocardium [J].Circulation, 2002, 105(24):2867-2871.